BrainStorm Cell Therapeutics, Inc.
OTC BB: BCLI
Executive Summary
October 2007
Contact information:
Chaim Levinson
Investor Relations Director
Clevinson@brainstorm-cell.com
Mobile: 972-545-633683
BrainStorm’s Value Proposition
BrainStorm is an early stage biotechnology company focused on developing innovative adult stem cell therapies for highly debilitating neurodegenerative disorders, such as Parkinson’s disease, Amyotrophic Lateral Sclerosis (also known as Lou Gehrig's disease), Multiple Sclerosis and spinal cord injury. Addressing the core pathology underlying neurodegenerative diseases rather than treating their symptoms, NurOwn™ treated patients are expected to enjoy a rapid recovery and much enhanced quality of life.
BrainStorm’s NurOwn™ therapy will provide—after full commercialization—compelling medical and economic benefits for patients, medical practitioners, and insurance/healthcare providers. By treating debilitating diseases,......
Join Now or Login to view the rest of this paper.
Approximate Word Count: 2603
Approximate Pages: 11 (260 words per double-spaced page) |